Mydecine Innovations Group Inc. (CSE:MYCO)

Market Cap	166.91K
Revenue (ttm)	n/a
Net Income (ttm)	2.29M
Shares Out	n/a
EPS (ttm)	1.85
PE Ratio	0.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,501
Average Volume	15,804
Open	0.2300
Previous Close	n/a
Day's Range	0.1850 - 0.2300
52-Week Range	0.1200 - 0.5000
Beta	1.83
RSI	43.82
Earnings Date	Mar 31, 2026

About CSE:MYCO

Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Mydecine Innovations...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: MYCO